Daniel V T Catenacci
Overview
Explore the profile of Daniel V T Catenacci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huffman B, Aushev V, Budde G, Chao J, Dayyani F, Hanna D, et al.
JCO Precis Oncol
. 2022 Dec;
6:e2200420.
PMID: 36480779
Purpose: Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in esophagogastric cancers (EGC) is less characterized...
2.
Wainberg Z, Enzinger P, Kang Y, Qin S, Yamaguchi K, Kim I, et al.
Lancet Oncol
. 2022 Oct;
23(11):1430-1440.
PMID: 36244398
Background: Outcomes are poor in patients with HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinomas. In this study, we investigated efficacy and safety of the first-in-class, afucosylated, humanised IgG1 anti-fibroblast growth...
3.
Shah M, Wainberg Z, Catenacci D, Hochster H, Ford J, Kunz P, et al.
PLoS One
. 2022 Oct;
17(10):e0276211.
PMID: 36215283
[This corrects the article DOI: 10.1371/journal.pone.0054014.].
4.
Powderly J, Klempner S, Naing A, Bendell J, Garrido-Laguna I, Catenacci D, et al.
Oncologist
. 2022 Sep;
27(11):905-e848.
PMID: 36156099
Background: Epacadostat, an oral, selective inhibitor of IDO1, has shown activity when administered with pembrolizumab. We evaluated the addition of chemotherapy to epacadostat and pembrolizumab in patients with advanced or...
5.
Palmer C, Rappaport A, Davis M, Hart M, Scallan C, Hong S, et al.
Nat Med
. 2022 Aug;
28(8):1619-1629.
PMID: 35970920
Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease control in combination with CPI therapy....
6.
Maron S, Moya S, Morano F, Emmett M, Chou J, Sabwa S, et al.
J Clin Oncol
. 2022 Mar;
40(22):2458-2467.
PMID: 35349370
Purpose: Subset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with amplified gastroesophageal adenocarcinoma (GEA), but large-scale analyses are lacking. This...
7.
Hsu P, Singh K, Dhiman A, Witmer H, He C, Eng O, et al.
JCO Precis Oncol
. 2022 Feb;
6:e2100337.
PMID: 35188804
Purpose: Current surveillance imaging and tumor markers lack sensitivity for the early detection of recurrence in GI cancers. This study critically evaluates the current literature on the role of sequential...
8.
Dhiman A, Vining C, Witmer H, Sood D, Shergill A, Kindler H, et al.
Ann Surg Oncol
. 2022 Jan;
PMID: 34988836
Background: Metastatic adenocarcinomas of foregut origin are aggressive and have limited treatment options, poor quality of life, and a dismal prognosis. A subset of such patients with limited metastatic disease...
9.
Shah M, Wainberg Z, Catenacci D, Hochster H, Ford J, Kunz P, et al.
PLoS One
. 2021 Dec;
16(12):e0261994.
PMID: 34941969
[This corrects the article DOI: 10.1371/journal.pone.0054014.].
10.
Paydary K, Reizine N, Catenacci D
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885039
To date, several trials have evaluated the safety and efficacy of immune-checkpoint inhibitors (ICI) for the treatment of gastroesophageal cancers (GEC). In the US, ICIs have established indications for second-line...